

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete If Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/527,679-Conf. #7223
				Filing Date	March 11, 2005
				First Named Inventor	Thomas FELZMANN
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	1	of	3	Attorney Docket Number	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	Date Considered	
-----------------------	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete If Known</i>	
				Application Number	10/527,679-Conf. #7223
				Filing Date	March 11, 2005
				First Named Inventor	Thomas FELZMANN
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	2	of	3	Attorney Docket Number	4518-0110PUS1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
CA	CZERNIECKI, Brian J. et al., "Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion", Cancer Res., February 15, 2007, Vol. 67, No. 4, pp. 1842-1852,			
CB	DAVIS, Daniel M., "Mechanisms and functions for the duration of intercellular contacts made by lymphocytes", Nature Reviews Immunology, August 2009, Vol. 9, pp. 543-555			
CC	DOHNAL, A. M. et al., "Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer", Cyotherapy, 2007, Vol. 9, No. 8, pp. 755-770,			
CD	DOHNAL, A. M. et al., "Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines", J. Cell. Mol. Med., 2009, Vol. 13, No. 1, pp. 125-135.			
CE	DOHNAL, A. M. et al., "CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression", J. Cell. Mol. Med., 2009, Vol. 13, No. 8, pp. 1741-1750.			
CF	FELZMANN, Thomas et al., "Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses", Cancer Immunol. Immunother., 2005, Vol. 54, pp. 769-780.			
CG	Huettnner, Katharaina Gabriele et al., "Generation of potent anti-tumor immunity in mice by interleukin-12 secreting dendritic cells", Cancer Immunol Immunother, 2005, Vo. 54, pp. 67-77.			
CH	Kalinski, Pawel et al., "Final maturation of dendritic cells is associated with impaired responsiveness to IFN- γ and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells", The Journal of Immunology, 1999, Vol. 162, pp. 3231-3236.			
CI	LANGENKAMP, Anja et al., "Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells", Nature Immunology, October 2000, Vol. 1, No. 4, pp. 311-316.			
CJ	LUO, Jun-Li et al., "IKK/NF- κ B signaling: balancing life and death - a new approach to cancer therapy", The Journal of Clinical Investigation, October 2005, Vol. 115, No. 10, pp. 2625-2632.			

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/527,679-Conf. #7223
				Filing Date	March 11, 2005
				First Named Inventor	Thomas FELZMANN
				Art Unit	1646
				Examiner Name	X. Xie
(Use as many sheets as necessary)				Attorney Docket Number	
Sheet	3	of	3	4518-0110PUS1	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.